OABI — OmniAb

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generatio...

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Industry

SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

Sector

Healthcare

Exchange

NASD

First trade date

2022-11-01

The interactive platform loads with JavaScript. Research tools are for informational purposes.